SCHEMBL4351835

SCHEMBL4351835

Cc1cccc(C2NCCc3sccc32)c1

nearest known ligand 0.70

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GID4 Q8IVV7 2/20 0.70
L3MBTL1 Q9Y468 1/20 0.52
HHAT Q5VTY9 2/20 0.46
HTR2C P28335 5/20 0.43
HTR2A P28223 3/20 0.43
PRCP P42785 2/20 0.40
KDM1A O60341 3/20 0.38
DRD3 P35462 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344078 0.82 GID4 (0.70) GID4L3MBTL1HTR2CHTR2APRCP
SCHEMBL4344185 0.81 GID4 (1.00) GID4L3MBTL1HTR2CHTR2APRCP
SCHEMBL20912489 0.81 GID4 (0.71) GID4L3MBTL1HHATPRCPKDM1A
SCHEMBL20912502 0.81 GID4 (0.71) GID4L3MBTL1HHATPRCPKDM1A
SCHEMBL2359018 0.81 GID4 (0.71) GID4L3MBTL1HHATPRCPKDM1A
SCHEMBL4357507 0.79 L3MBTL1 (0.71) GID4L3MBTL1HTR2CHTR2AKDM1A
SCHEMBL12761049 0.77 GID4 (0.60) GID4L3MBTL1HHATHTR2CPRCP
SCHEMBL22728766 0.76 PRCP (0.69) GID4HTR2CHTR2APRCPKDM1A
SCHEMBL28338936 0.76 PRCP (0.69) GID4HTR2CHTR2APRCPKDM1A
SCHEMBL29498351 0.76 PRCP (0.69) GID4HTR2CHTR2APRCPKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350093-B1 SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE GRUENENTHAL GMBH (DE) 2012-10-03 EP disclosed
US-8268814-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-8268814-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-8268814-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed
WO-2009124746-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS BDKRB2, BDKRB1, TRPV1 GID4 2638/4885L3MBTL1 4835/4885HHAT 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.